Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced preclinical findings on ensovibep, a tri-specific DARPin therapeutic targeting SARS-CoV-2, published in Nature Biotechnology. Key results demonstrate ensovibep's ability to bind to all units of the viral spike protein, inhibiting ACE2 interaction. It shows efficacy against SARS-CoV-2 variants, including Omicron strains. These findings support ongoing clinical development for Emergency Use Authorization by the FDA. Molecular Partners plans to expand its antiviral DARPin portfolio for future health threats.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced its participation in several key conferences in June 2022, highlighting developments in their DARPin therapeutics aimed at treating various diseases. At the European Hematology Association Conference, they will present data on MP0533, a T-cell engager targeting tumors. Additionally, Novartis will showcase preclinical data on ensovibep, a COVID-19 treatment. Presentations also include discussions on ensuring safety and efficacy for AML therapies. Further details can be accessed via their official website.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 - Molecular Partners (SIX: MOLN; NASDAQ: MOLN) announced its interim management statement for Q1 2022, showcasing a strong cash position of CHF 296.2 million and revenue of CHF 172.8 million, largely from Novartis's exercise of its option for ensovibep. Positive Phase 2 results for ensovibep demonstrated a 78% reduction in hospitalization risks. The company is advancing its internal pipeline, including new candidates MP0310 and MP0533, and is expected to be funded into 2026.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm specializing in DARPin therapeutics, will participate in two investor events in May. The company is set to publish its Q1 2022 earnings report on May 12, 2022, after NASDAQ trading hours. Key events include the RBC Capital Markets Global Healthcare Conference from May 17-18, featuring a fireside chat on May 17 at 9:00 am ET, and BioEquity Europe 2022 with virtual meetings on May 23-24. Presentations will be available online.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that CEO Patrick Amstutz has been elected President of the Swiss Biotech Association. This leadership change signifies a commitment to fostering collaboration within the biotech sector, especially in response to global medical needs. Dr. Amstutz aims to support the growth of the Swiss biotech ecosystem, emphasizing the importance of innovation. He succeeds Dominik Escher, who held the position for 20 years. The announcement coincided with Dr. Amstutz's participation in a panel discussion on pandemic response strategies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the return of global rights for MP0310 from Amgen following a strategic review. MP0310, targeting FAP and 4-1BB, is currently in a Phase 1 trial, with full data expected later this year. Initial results show promise in activating immune responses in tumor microenvironments. This collaboration, started in December 2018, included a $50 million upfront payment, but no further clinical studies are planned until discussions with potential new partners post-trial completion.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) provides an update following Novartis' quarterly earnings call, where CEO Vas Narasimhan mentioned that the Emergency Use Application (EUA) for ensovibep requires additional clinical data for FDA authorization. The ongoing omicron wave complicates clinical investigations. Novartis is coordinating with the FDA to design a potential Phase 3 study to gather necessary data for EUA or full approval. Molecular Partners continues to develop its DARPin therapeutics in collaboration with major pharmaceutical companies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that late-breaker data from the EMPATHY study of ensovibep will be presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases in Lisbon from April 23-26, 2022. Dr. N. Kumarasamy will present interim results from the phase II/III study focused on mild-to-moderate COVID-19 patients. Additionally, a symposium on COVID-19 variants and DARPin therapeutic efficacy will occur on April 26, featuring insights from Novartis and Molecular Partners' executives.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company, announced participation in the Kempen Life Sciences investor conference on April 20-21, 2022. CFO Andreas Emmenegger and COO Michael Stumpp will present on April 20 at 16:30 CET (10:30 AM EDT). The company focuses on developing DARPin therapeutics, a new class of custom-built protein drugs aimed at addressing unmet medical needs in areas like infectious disease and oncology. More details will be available on the Molecular Partners website.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that all shareholder motions were approved during its recent Annual General Meeting. Key outcomes included the re-election of the Board of Directors, with Bill Burns remaining as Chairman. KPMG AG Zurich was confirmed as statutory auditors for 2022. Shareholders authorized the Board to increase share capital until April 2024 and approved the annual financial statements for 2021. The meeting was conducted virtually due to COVID-19 regulations, without physical attendance.